

Peter Webse

From: ASXMarket.AnnouncementsOffice@asx.com.au
Sent: Tuesday, 16 February 2016 6:21 AM
To: ASXMarket.AnnouncementsOffice@asx.com.au
Subject: Confirmation of Release - CYP - Cynata Receives \$930k R&D Tax Incentive Refund
Attachments: 1525140.pdf

ASX confirms the release to the market of Doc ID: 1525140 as follows:

Release Time: 16-FEB-2016 09:21:22

ASX Code: CYP

Related ASX Codes:

Announcement Title: Cynata Receives \$930k R&D Tax Incentive Refund

*** THIS IS AN AUTO GENERATED EMAIL. DO NOT REPLY TO THE SENDER OF THIS EMAIL. THIS MAILBOX IS NOT MONITORED. PDF will only be attached to this email if the size is less than 5MB. To view released announcements please go to www.asx.com.au ****

**** This email is being received because the mentioned listed entity chose to include this email address as a recipient. Do not sell or distribute its content inappropriately.****

*** Please contact the ASX Market Announcements office for assistance on 1800 021 965. *** The information in this email is confidential, it may also be privileged and is intended for the exclusive use of the addressee(s). If you have received this email in error, please do not distribute it, notify me and destroy the original message and all copies. The unauthorised use of this email may result in liability for breach of confidentiality, privilege or copyright. E-mail transmissions cannot be guaranteed to be secure or error-free as information could be intercepted, corrupted, lost, destroyed, arrive late or incomplete or contain viruses. The sender does not accept liability for errors or omissions in the contents of this message which arise as a result of e-mail transmission.



ASX ANNOUNCEMENT

Cynata Receives \$930k R&D Tax Incentive Refund

Melbourne, Australia; 16 February 2016: Australian stem cell and regenerative medicine company, Cynata Therapeutics Ltd (ASX: CYP), is pleased to announce that the Company has received an R&D Tax Incentive refund of \$932,580.65 for the 2014/2015 financial year.

“The R&D Tax Incentive is an important program and this refund provides a very useful addition to the Company’s balance sheet and extends our operating runway at a time when we plan to soon commence the clinical trial of our first proprietary Cymerus™ mesenchymal stem cell (MSC) product, CYP-001”, said Dr Ross Macdonald, Cynata’s Chief Executive Officer.

The R&D Tax Incentive is an Australian Government program under which companies receive cash refunds of 45% of eligible expenditure on research and development.

About Cynata Therapeutics (ASX: CYP)

Cynata Therapeutics Limited (ASX: CYP) is an Australian stem cell and regenerative medicine company that is developing a therapeutic stem cell platform technology, Cymerus™, originating from the University of Wisconsin-Madison, a world leader in stem cell research. The proprietary Cymerus™ technology addresses a critical shortcoming in existing methods of production of mesenchymal stem cells (MSCs) for therapeutic use, which is the ability to achieve economic manufacture at commercial scale. Cymerus™ does so through the production of a particular type of MSC precursor, called a mesenchymoangioblast (MCA). The Cymerus™ MCA platform provides a source of MSCs that is independent of donor limitations and provides a potential “off-the-shelf” stem cell platform for therapeutic product use, with a pharmaceutical business model and economies of scale. This has the potential to create a new standard in the emergent arena of stem cell therapeutics and provides both a unique differentiator and an important competitive position.

CONTACTS: Dr Ross Macdonald, CEO: Tel: 0412 119343; email ross.macdonald@cynata.com
Dr Stewart Washer, Executive Chairman: Tel: 0418 288212; email stewart.washer@cynata.com
Kirin Smith, Chief Operations Officer, Investor Contact, + 1 646-863-6519, ksmith@pcgadvisory.com
Sean Leous, Chief Communications Officer, Media Contact, +1 646-863-8998, sleous@pcgadvisory.com
Rudi Michelson, Monsoon, Australia Media Contact, 0411 402 737, rudim@monsoon.com.au